TAK-500

N/A

Report date: 2025/03/24 11:28:51

First In Class

Base Information

Drug NameTAK-500

Drug Alias NameTAK-500

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > TAK-676 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionStimulator of interferon genes stimulantsAnti-C-C chemokine receptor type 2

TargetsStimulator of interferon genesC-C chemokine receptor type 2

Therapy Area/IndicationsKidney NeoplasmsNasopharyngeal NeoplasmsPancreatic Neoplasms +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakeda Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsKidney NeoplasmsNasopharyngeal NeoplasmsPancreatic Neoplasms +[9]

Other Information

ATC CodeN/A